ClinicalTrials.gg
Not yet recruitingNCT07939347Updated Nov 16, 2026

AVATAR Therapy for Distressing Voices in India and Ethiopia

An interventional study of AVATAR Therapy in Psychosis and Hallucinations, sponsored by King's College London. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by King's College London · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Psychotic Disorders by King's College London — 12 open to participants now, 12 under way, none of them phase 3. Psychotic Disorders · King's College London.

Planned enrollment
7th of 18
30 · median 24
Started
2026
with 2 others
No phase
15 of 26
5 open now
Primary completion
2027-09
later than 5 of 11 live
Registered
26th of 26
by date

Among the 26 studies in Psychotic Disorders by King's College London, this one is the 7th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2026, is one of 15 with no phase, reaches primary completion later than 5 of the 11 other live ones, and was the 26th registered.

Psychotic Disorders

1,589 studies on the registry are indexed under Psychotic Disorders; 280 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

12 of the 26 studies in Psychotic Disorders by King's College London are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Psychotic Disorders by King's College London, or all of them as a file.
02

Study summary

This study evaluates the feasibility, acceptability, and safety of contextually adapted AVATAR therapy for people experiencing distressing voices associated with psychosis in Ethiopia and India. AVATAR therapy is a psychological intervention in which participants create a digital avatar representing a distressing voice and engage in therapist-supported dialogues with the avatar.

Thirty participants (15 in Ethiopia and 15 in India) will receive culturally adapted AVATAR therapy. Participants will complete assessments at baseline, 12 weeks, and 24 weeks. The study will assess feasibility of recruitment and retention, acceptability of the intervention, safety, and preliminary changes in voice-related distress, beliefs about voices, emotional wellbeing, and functioning. Qualitative interviews will explore participants' and therapists' experiences of the intervention and its cultural relevance.

Read the detailed description

AVATAR therapy is a psychological intervention for distressing auditory verbal hallucinations in which participants create a visual and vocal representation of a distressing voice and engage in structured dialogue with that avatar under the guidance of a trained therapist. The intervention seeks to reduce voice-related distress, improve perceived control over voices, and support recovery.

This multicentre international case series aims to evaluate the feasibility, acceptability, and safety of culturally adapted AVATAR therapy in Ethiopia and India. Adaptations have been informed by stakeholder engagement, service-user involvement, clinician feedback, and local cultural considerations.

Participants meeting eligibility criteria will complete a baseline assessment and receive up to 12 sessions of culturally adapted AVATAR therapy. Follow-up assessments will be completed at 12 weeks and 24 weeks after baseline. Quantitative measures will assess feasibility, acceptability, voice-related outcomes, emotional wellbeing, and functioning. Qualitative interviews will explore participant and therapist experiences of the intervention and identify factors relevant to future implementation and evaluation. The study is not powered to determine efficacy but will provide preliminary evidence regarding implementation and clinical outcomes in these settings.

03

Conditions studied

  • Psychosis
  • Hallucinations

Keywords

  • AVATAR therapy
  • distressing voices
  • psychosis
  • schizophrenia
  • digital mental health
  • feasibility study
  • psychological therapy
  • global mental health
  • cultural adaptation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Experience distressing and frequent auditory verbal hallucinations (voices) for at least 6 months.
  • Score of at least 1 on both the frequency and distress items of the Psychotic Symptom Rating Scales Auditory Hallucinations Subscale (PSYRATS-AH).
  • Meet diagnostic criteria for a schizophrenia spectrum disorder (ICD-11 F20-F29) or an affective disorder with psychotic symptoms (ICD-11 F30-F39 with psychotic symptoms).
  • Willing and able to participate in AVATAR therapy.
  • Able to provide .

Exclusion criteria

Exclusion Criteria:

  • Acute mental health crisis requiring immediate intervention.
  • Primary diagnosis of substance use disorder.
  • Learning disability that would prevent engagement with the intervention or study procedures.
  • Lack of capacity to provide .
  • Severe visual or hearing impairment that would prevent participation in AVATAR therapy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Contextually Adapted AVATAR Therapy

    Participants will receive contextually adapted AVATAR therapy delivered by trained clinicians.

    Behavioral: AVATAR Therapy

Interventions

  • BehavioralAVATAR Therapy

    AVATAR therapy is a psychological intervention for distressing voices in which participants create a visual and vocal avatar representing a distressing voice and engage in structured therapist-supported dialogues. Participants attend up to 12 therapy sessions. Dialogues aim to reduce voice-related distress by targeting the relationship between the individual and the voice while promoting increased control, empowerment and recovery. Adaptations have been developed for implementation in Ethiopia and India through stakeholder engagement and cultural adaptation processes.

06

What researchers measure

Primary outcomes

  1. Recruitment feasibility

    Number of participants recruited at each site within the recruitment period. Feasibility is indicated by successful recruitment of 15 participants per site.

    Time frame: 9 months

  2. Therapy completion

    Proportion of participants completing the minimum therapy dose (defined as at least 4 therapy sessions involving an avatar dialogue). Feasibility target is ≥70% completion.

    Time frame: Up to 12 weeks

  3. Retention to follow-up

    Proportion of participants completing 12-week and 24-week follow-up assessments.

    Time frame: 24 weeks from baseline assessment

  4. Acceptability of AVATAR Therapy: Client Satisfaction Questionnaire (CSQ-8)

    Eight-item measure assessing participant satisfaction with the intervention. Scores range from 8 to 32, with higher scores indicating greater satisfaction.

    Time frame: 12 weeks (end of therapy assessment)

  5. Acceptability: Acceptability of Intervention measure (AIM) service user rating

    4-item acceptability measure completed by service users. Higher scores indicate higher perceived acceptability of the intervention.

    Time frame: 12 weeks (end of therapy assessment)

  6. Safety of AVATAR therapy assessed through monitoring of adverse events

    Number and nature of adverse events, serious adverse events, and intervention-related adverse events occurring during participation.

    Time frame: Time Frame: Baseline to 24 weeks.

  7. Therapist-rated intervention appropriateness

    The Intervention Appropriateness Measure (IAM) is a 4-item implementation outcome measure assessing clinicians' perceptions of the fit, relevance, suitability, and appropriateness of AVATAR therapy within their clinical setting. Four items rated on a 5-point Likert scale from 1 (Completely Disagree) to 5 (Completely Agree). Higher scores indicate greater perceived appropriateness of the intervention.

    Time frame: Following completion of intervention delivery (approximately 12 weeks)

  8. Therapist-rated Feasibility of Intervention Measure (FIM)

    The Feasibility of Intervention Measure (FIM) is a 4-item implementation outcome measure assessing clinicians' perceptions of the extent to which AVATAR therapy can be successfully used or carried out within their clinical setting. Four items rated on a 5-point Likert scale from 1 (Completely Disagree) to 5 (Completely Agree). Higher scores indicate greater perceived feasibility of the intervention.

    Time frame: Following completion of intervention delivery (approximately 12 weeks)

  9. Acceptability: Acceptability of Intervention measure (AIM) therapist rating

    4-item acceptability measure completed by therapists. Higher scores indicate higher perceived acceptability of the intervention.

    Time frame: Following completion of intervention delivery (approximately 12 weeks)

Secondary outcomes

  1. Psychotic Symptom Rating Scales - Auditory Hallucinations Subscale (PSYRATS-AH)

    Clinician-rated assessment of auditory hallucination severity and associated distress. 11 items scored 0-4; higher scores indicate greater severity and distress.

    Time frame: Baseline, 12 weeks, and 24 weeks.

  2. Beliefs About Voices Questionnaire - Revised (BAVQ-R)

    Assessment of beliefs and emotional/behavioural responses to voices. 35 items scored 0-3 across malevolence, benevolence, omnipotence, resistance, and engagement domains. Higher subscale scores indicate stronger endorsement of the corresponding belief or response to voices.

    Time frame: Baseline, 12 weeks, and 24 weeks.

  3. Voice Power Differential Scale

    Participant rating of the relative power of the voice compared with themselves. Single-item measure scored 1-5. Higher scores indicate greater perceived power and dominance of the voice relative to the individual, whereas lower scores indicate a more balanced relationship or greater perceived personal power.

    Time frame: Baseline, 12 weeks, and 24 weeks.

  4. Patient Health Questionnaire (PHQ-9)

    Self-report measure of depressive symptoms during the previous two weeks. 9 items scored 0-3; total score range 0-27, with higher scores indicating greater depression severity.

    Time frame: Baseline, 12 weeks, and 24 weeks.

  5. Generalized Anxiety Disorder-7 (GAD-7)

    Anxiety symptoms assessed using the Generalized Anxiety Disorder-7 (GAD-7), a 7-item self-report measure of anxiety symptoms experienced over the previous two weeks. Participants rate how often they have been bothered by symptoms such as feeling nervous, worrying excessively, and difficulty relaxing. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity.

    Time frame: Baseline, 12 weeks, and 24 weeks.

  6. World Health Organization Disability Assessment Schedule (WHODAS-12)

    Self-report assessment of disability and functional impairment. 12-item measure; higher scores indicate greater disability.

    Time frame: Baseline, 12 weeks, and 24 weeks.

  7. World Health Organization Well-Being Index (WHO-5)

    Self-report measure of subjective wellbeing. Five items scored 0-5; higher scores indicate greater wellbeing.

    Time frame: Baseline, 12 weeks, and 24 weeks.

  8. Sessional ratings of Voice-Related and Recovery Outcomes

    Participant-completed sessional measure comprising 9 items assessing voice-related distress, voice frequency, social connection, progress towards important goals, perceived power of the voice, along with sense of voice presence and emotional responses during AVATAR therapy (including anxiety, anger, and confidence in relation to the voice dialogue). Measures are completed during each therapy session, with items 1-5 completed before the avatar dialogue and items 6-9 completed following the dialogue. Each construct is assessed using a single item and may be analysed independently. Higher scores indicate greater endorsement of the construct being measured; interpretation therefore varies according to the specific construct assessed.

    Time frame: Each session during therapy (up to 12 weeks)

  9. Goal Based Outcomes

    Progress towards a participant-identified personal recovery goal. At baseline, participants identify one personally meaningful goal for therapy and rate their current progress. Progress towards this goal is subsequently rated on an 11-point scale ranging from 0 ("goal not met at all") to 10 ("goal fully achieved"). Higher scores indicate greater attainment of the participant's personal goal.

    Time frame: Baseline, 12 weeks, 24 weeks

Other outcomes

  1. Therapeutic Alliance - Helping Alliance Questionnaire-II (HAq-II)

    Therapeutic alliance assessed using the Helping Alliance Questionnaire-II (HAq-II), a 19-item participant-reported measure of the quality of the therapeutic relationship, including collaboration, trust, and perceived helpfulness of therapy. Higher scores indicate a stronger therapeutic alliance.

    Time frame: 12 weeks

  2. Service-user rated match of digital avatar to their distressing voice

    Two items assessing the match between the digital avatar and their distressing voice, in terms of the voice (Q1) and image (Q2). Both are rated once after avatar creation (takes place between session 1-3) on a 0-10 scale, where a higher score indicates a more accurate representation of their distressing voice experience.

    Time frame: Within 3 weeks of baseline assessment

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in publications arising from this study may be made available to qualified researchers upon reasonable request. Requests will be reviewed by the study investigators and sponsor (King's College London) and may require appropriate ethical approvals and a data-sharing agreement. Supporting documentation including the study protocol and data dictionary may also be made available.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: 10 years

Access criteria: De-identified individual participant data underlying the results reported in publications arising from this study may be made available to qualified researchers upon reasonable request. Requests must include a scientifically sound research proposal and evidence of appropriate institutional and ethical approvals where required. Requests will be reviewed by the study investigators and sponsor (King's College London). Data sharing may be subject to a data sharing agreement and compliance with applicable legal, ethical, and data protection requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Sep 2027, 10 months later.

Of 457 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 10 months is below that.

Counting every sponsor, half of 459 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Nov 12, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939347
Collaborators
Addis Ababa University, All India Institute of Medical Science, New Delhi
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 12, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Rebecca Lougher, PhD DClinPsy
Contact
rebecca.3.kelly@kcl.ac.uk
07823684248
Thomas Ward, PhD DClinPsy
Contact
thomas.ward@kcl.ac.uk
Thomas Ward, PhD DClinPsy
principal investigator · King's College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion